Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in MTOR

Objective: To define causative somatic mutations in resected brain tissue from an infant with intractable epilepsy secondary to hemispheric cortical dysplasia. Methods: Whole-exome sequencing was conducted on genomic DNA derived from both resected brain tissue and peripheral blood leukocytes. Comparison of the brain vs blood sequencing results was performed using bioinformatic methods designed to detect low-frequency genetic variation between tissue pairs. Results: Histopathology of the resected tissue showed dyslamination and dysmorphic neurons, but no balloon cells, consistent with focal cortical dysplasia type IIa. mTOR activation was observed by immunohistochemistry in the dysplasia. A missense mutation (c.4487T>G; p.W1456G) was detected in the FAT domain of MTOR in DNA from the dysplasia but not in lymphocytes. The mutation is predicted damaging (i.e., leading to mTOR activation) and was observed as a low-level mosaic with 8% of cells being heterozygous for the variant. Conclusions: We report the novel finding of an MTOR mutation associated with nonsyndromic cortical dysplasia. Somatic-specific mutations in MTOR and related genes should be considered in a broader spectrum of patients with hemispheric malformations and more restricted forms of cortical dysplasia.

[1]  J. Shendure,et al.  Somatic mutations in cerebral cortical malformations. , 2014, The New England journal of medicine.

[2]  I. Scheffer,et al.  Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations , 2014, Annals of neurology.

[3]  I. Scheffer,et al.  Is focal cortical dysplasia sporadic? Family evidence for genetic susceptibility , 2014, Epilepsia.

[4]  Andrew H. Beck,et al.  A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. , 2014, Cancer discovery.

[5]  M. Xing,et al.  Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity* , 2013, The Journal of Biological Chemistry.

[6]  Eleonora Aronica,et al.  Detection of human papillomavirus in human focal cortical dysplasia type IIB , 2012, Annals of neurology.

[7]  S. Gabriel,et al.  De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly , 2012, Nature Genetics.

[8]  J. Shendure,et al.  De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes , 2012, Nature Genetics.

[9]  P. Crino mTOR: A pathogenic signaling pathway in developmental brain malformations. , 2011, Trends in molecular medicine.

[10]  Maria Thom,et al.  The clinicopathologic spectrum of focal cortical dysplasias: A consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission 1 , 2011, Epilepsia.

[11]  D. Sabatini,et al.  DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival , 2009, Cell.